En direct

Le Centre de Recherche en Cancérologie de Marseille fête ses 50 ans ! -

Feb 2019 Molecular and clinical oncology

Inflammatory breast cancer in 210 patients: A retrospective study on epidemiological, anatomo-clinical features and therapeutic results.


Manai M, Finetti P, Mejri N, Athimni S, Birnbaum D, Bertucci F, Rahal K, Gamoudi A, Chaffanet M, Boussen H


To report epidemiological and anatomo-clinical features within a retrospective series of inflammatory breast cancer and to evaluate prognostic factors. This retrospective study included 210 Tunisian patients presenting a clinically diagnosed IBC, treated at the Institute Salah Azaiez (ISA) of Tunis, Tunisia, from 2008 to 2013. We collected data on epidemiology, anatomo-clinical and biological features and histologic response to neoadjuvant therapy. Overall and disease-free survivals were calculated by Kaplan-Meier method and compared by log-rank tests and Cox’s models were used to identify prognostic factors impacting survival. The 210 IBC patients had a median age of 42 years (24-62) and 15% of them were aged less than 35 years. Mean age at menarche was 13 years and 45% had their 1st childbirth before 23 years. On histology, grades III represented 42% of cases, hormone receptors were negative in 59%, HER2 over-expressed in 32, 25% of our IBC cases had a triple negative profile and Ki-67 was >20% in 53% of cases. High pathological grade III was significantly correlated to TN subtype (58%) (Fisher’s exact test, P=7.5×10). Further, high Ki-67 expression (>20%) was evident in the TN subtype (84%) (Fisher’s exact test, P=3.7×10). After neoadjuvant therapy (and trastuzumab in 88 and 69% of HER2+ patients, respectively), we observed 49% of objective clinical responses and 35% of pathological complete response (pCR) and >3 axillary lymph nodes were invaded on a resected tumor in 55% of cases. Overall survival (OS) was associated with age at menarche (Wald-test, P=2.2×10) and metastases at diagnosis (Wald-test, P=2.4×10). Reaching a pCR was correlated with a better metastasis-free survival (MFS), (Fisher’s exact test, P=3.6×10).

Lire l‘article